Market Place
Sourcing Support
Lyra Therapeutics Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
Lyra Therapeutics Fully Enrolls Phase 3 Trial Of LYR-210
15 Oct 2024 //
GLOBENEWSWIRE
Lyra Therapeutics To Present LYR-210 And LYR-220 Study Results
27 Sep 2024 //
GLOBENEWSWIRE
Lyra Therapeutics Reports Q2 2024 Financial Results And Corporate Update
14 Aug 2024 //
GLOBENEWSWIRE
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
21 May 2024 //
GLOBENEWSWIRE
Lyra Reports Topline Phase 3 LYR-210 Chronic Sinusitis Data
06 May 2024 //
GLOBENEWSWIRE
Lyra Reports Q1 2024 Results, Provides Corporate Update
30 Apr 2024 //
GLOBENEWSWIRE
Lyra Announces Inducement Grants Under Nasdaq Rule
26 Apr 2024 //
GLOBENEWSWIRE
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
Lyra Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Mar 2024 //
GLOBENEWSWIRE
Lyra Therapeutics to Participate in Upcoming Investor Conferences
07 Nov 2023 //
GLOBENEWSWIRE
Lyra Therapeutics Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Lyra Therapeutics Announces Appointment of Ronan O™Brien as Chief Legal Officer
16 Oct 2023 //
GLOBENEWSWIRE
Lyra touts positive topline PhII data for chronic rhinosinusitis drug
12 Sep 2023 //
ENDPTS
Lyra Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220
12 Sep 2023 //
GLOBENEWSWIRE
Lyra Therapeutics to Participate in Upcoming Investor Conferences
06 Sep 2023 //
GLOBENEWSWIRE
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210
29 Aug 2023 //
GLOBENEWSWIRE
Lyra Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference
13 Jul 2023 //
GLOBENEWSWIRE
Lyra Therapeutics to Present at Jefferies Healthcare Conference
02 Jun 2023 //
GLOBENEWSWIRE
Lyra Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02 Jun 2023 //
GLOBENEWSWIRE
Lyra Therapeutics Announces Closing of $50.0 Million Private Placement
01 Jun 2023 //
GLOBENEWSWIRE
Lyra Therapeutics Announces $50.0 Million Private Placement
26 May 2023 //
GLOBENEWSWIRE
Lyra Therapeutics Reports First Quarter 2023 Financial Results
12 May 2023 //
GLOBENEWSWIRE
Lyra Therapeutics to Present at Bank of America Securities 2023 Conference
09 May 2023 //
GLOBENEWSWIRE
Lyra Announces Restart of Pivotal Ph3 ENLIGHTEN II Trial of LYR-210
25 Apr 2023 //
GLOBENEWSWIRE
Lyra Reports Fourth Quarter and Full Year 2022 Financial Results
29 Mar 2023 //
GLOBENEWSWIRE
Lyra Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer
27 Feb 2023 //
GLOBENEWSWIRE
Lyra Announces Completion of Enrollment in the BEACON Phase 2 Trial of LYR-220
06 Feb 2023 //
GLOBENEWSWIRE
Lyra Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17 Jan 2023 //
GLOBENEWSWIRE
Lyra Therapeutics to Present at Upcoming Investor Conferences
09 Nov 2022 //
GLOBENEWSWIRE
Lyra Therapeutics Reports3Q 2022 Financial Results and Provides Corporate Update
08 Nov 2022 //
GLOBENEWSWIRE
Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220
13 Sep 2022 //
PRNEWSWIRE
Lyra Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
13 Sep 2022 //
PRNEWSWIRE
Lyra Therapeutics enrols first subject in Phase III CRS therapy trial
09 Sep 2022 //
CLINICALTRIALSARENA
Lyra Announces First Patient Enrolled in Pivotal ENLIGHTEN II Trial of LYR-210
08 Sep 2022 //
PRNEWSWIRE
Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as CMO
05 Jul 2022 //
PRNEWSWIRE
Lyra Tx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17 Jun 2022 //
PRNEWSWIRE
Lyra Therapeutics to Present at Upcoming Investor Conferences
05 May 2022 //
PRNEWSWIRE
Lyra Presents Positive Data From Lantern Phase 2 Study Of LYR-210
29 Apr 2022 //
PRESS RELEASE
Lyra treats first subject in Phase II rhinosinusitis treatment trial
25 Apr 2022 //
CLINICALTRIALSARENA
A First Look At Lyra Therapeutics
21 Apr 2022 //
SEEKING ALPA
Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022
21 Apr 2022 //
PRNEWSWIRE
Lyra Therapeutics Announces Closing Of $100.5 Million Private Placement
13 Apr 2022 //
PRESS RELEASE
Lyra Therapeutics Announces $100.5 Million Private Placement
08 Apr 2022 //
PRESS RELEASE
Lyra Tx Announces First Patient in Pivotal ENLIGHTEN I Clinical Trial of LYR-210
28 Feb 2022 //
PRNEWSWIRE
Lyra Therapeutics Appoints Harlan W. Waksal, MD, as Executive Chairman
17 Feb 2022 //
PRNEWSWIRE
Lyra Initiates LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Rhinosinusitis
24 Jan 2022 //
PRNEWSWIRE
Lyra Reports Q3 2021 Financial Results and Provides Corporate Update
09 Nov 2021 //
PRNEWSWIRE
Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up
04 Oct 2021 //
PRNEWSWIRE
Lyra Therapeutics Announces 4 Abstracts to Present at Upcoming ERS & ARS Meeting
20 Sep 2021 //
GLOBENEWSWIRE
Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31
17 Aug 2021 //
GLOBENEWSWIRE
Lyra Therapeutics to Report Second Quarter 2021 Financial Results on August 9
26 Jul 2021 //
GLOBENEWSWIRE
Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference
12 Jul 2021 //
GLOBENEWSWIRE
Lyra Announces Positive Topline Results of Pharmacokinetic Study of LYR-210
30 Jun 2021 //
GLOBENEWSWIRE
Lyra Therapeutics Announces Positive Outcome Update for LYR-210
08 Jun 2021 //
BUSINESSWIRE
Lyra Therapeutics taps LianBio to bring sinusitis med to Asia
02 Jun 2021 //
FIERCEBIOTECH
Lyra Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210
13 Apr 2021 //
BUSIESSWIRE
Lyra Therapeutics to Present LANTERN Phase 2 Study Results for LYR?210
29 Mar 2021 //
BUSINESSWIRE
Lyra Therapeutics to Present LANTERN Phase 2 Study Results for LYR?210
29 Mar 2021 //
BUSINESSWIRE
